Fennec Pharmaceuticals (TSE:FRX - Get Free Report) is scheduled to issue its quarterly earnings data before the market opens on Thursday, November 7th. Analysts expect the company to announce earnings of C($0.19) per share for the quarter.
Fennec Pharmaceuticals (TSE:FRX - Get Free Report) last posted its quarterly earnings results on Tuesday, August 13th. The biopharmaceutical company reported C($0.27) earnings per share (EPS) for the quarter, missing the consensus estimate of C$0.08 by C($0.35). Fennec Pharmaceuticals had a net margin of 5.59% and a negative return on equity of 1,005.59%. The firm had revenue of C$9.94 million for the quarter, compared to analyst estimates of C$18.67 million.
Fennec Pharmaceuticals Stock Performance
FRX stock traded down C$0.02 during trading on Friday, hitting C$6.08. 910 shares of the company's stock traded hands, compared to its average volume of 1,819. The stock has a market capitalization of C$166.35 million, a price-to-earnings ratio of 60.80 and a beta of 0.25. Fennec Pharmaceuticals has a 52 week low of C$5.76 and a 52 week high of C$15.43. The stock has a fifty day moving average price of C$6.78 and a two-hundred day moving average price of C$8.71. The company has a quick ratio of 10.17, a current ratio of 8.02 and a debt-to-equity ratio of 1,040.68.
About Fennec Pharmaceuticals
(
Get Free Report)
Fennec Pharmaceuticals Inc operates as a biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. It sells its products through regional pediatric oncology specialists and medical science liaisons.
Featured Stories
Before you consider Fennec Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Fennec Pharmaceuticals wasn't on the list.
While Fennec Pharmaceuticals currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
